At 11: 00 am ET today (November 2, 2021), the outcomes will be launched for research study that examined the efficiency of the Johnson & &(********************************************************************************** )vaccine for avoiding COVID-19 The research study will be released in JAMA Network Open, a month-to-month open gain access to medical journal released by the American Medical Association.
What The Study Did: The findings of this research study, that included 8,889 clients who got a single dosage of the Advertisement26 COV2.S (Johnson & & Johnson) COVID-19 vaccine and 88,898 unvaccinated clients, follow the medical trial– reported effectiveness of Advertisement26 COV2.S, recommending that the vaccine works at minimizing SARS-CoV-2 infection, even with the spread of versions such as Alpha or Delta that were not present in the initial research studies, and declare the immediate requirement to continue mass vaccination efforts worldwide.
Authors: Tyler Wagner,Ph D., and Venky Soundararajan,Ph D., of nference in Cambridge, Massachusetts, are the matching authors.
In the research study, the occurrence rate of SARS-CoV-2 infection was 60 out of 8889 immunized clients vs 2236 of 88,898 unvaccinated people. This represents an efficiency of 73.6%, occurrence rate ratio of 0.26, and a 3.73- fold decrease in SARS-CoV-2 infections.
Link: JAMA Network Open
Reference: “Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19” by Juan Corchado-Garcia, Ph D; David Zemmour, MD, Ph D; Travis Hughes, MD, Ph D; Hari Bandi, Ph D; Tudor Cristea-Platon, Ph D; Patrick Lenehan, BS; Colin Pawlowski, Ph D; Sairam Bade, BS; John C. O’Horo, MD; Gregory J. Gores, MD; Amy W. Williams, MD; Andrew D. Badley, MD; John Halamka, MD; Abinash Virk, MD; Melanie D. Swift, MD, MILES PER HOUR; Tyler Wagner, Ph D and Venky Soundararajan, Ph D, 2 November 2021, JAMA Network Open
DOI: 10.1001/ jamanetworkopen.202132540
